Challenge of raiditoherapy for oral cancer -definition of appropriate combination both cetuximab and docetaxel-

2016 Fiscal Year Final Research Report

• Project/Area Number: 26462838
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Pathobiological dentistry/Dental radiology
• Research Institution: The University of Tokushima
• Principal Investigator: KUDOH Takaharu 徳島大学, 大学院医歯薬学研究部(歯学系), 助教 (10263865)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 癌 / 細胞実験 / 放射線照射 / ドセタキセル / セツキシマブ

Outline of Final Research Achievements

Before, during and after irradiation, determine an appropriate combinaton both cetuximab and docetaxel in vitro using analyses of colony formation assay and apoptosis. First, in vitro experiment to B88 cell and CAL27 cell. In the analysis, it became clear that 4 Gy was an appropriate dose and docetaxel was 4 ng/ml, cetuximab was 25 microg/ml in 2 hour processing. The significant difference was not accepted even if it prescribed docetaxel or cetuximab for each period of irradiation. There is a mission which determines an appropriate combination by other medicines and irradiation in vitro and vivo from now on, and determines the regimen of the optimal organ preservation treatment.

Free Research Field

放射線腫瘍学